Published in Pathophysiology on February 01, 2011
Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal (2012) 1.82
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (2012) 1.75
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
The role of antigen presenting cells in multiple sclerosis. Biochim Biophys Acta (2010) 1.38
Demyelination reduces brain parenchymal stiffness quantified in vivo by magnetic resonance elastography. Proc Natl Acad Sci U S A (2012) 1.24
The innate immune system in demyelinating disease. Immunol Rev (2012) 1.10
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol (2015) 1.05
Animal models used to examine the role of the environment in the development of autoimmune disease: findings from an NIEHS Expert Panel Workshop. J Autoimmun (2012) 1.05
Animal Models of MS Reveal Multiple Roles of Microglia in Disease Pathogenesis. Neurol Res Int (2011) 1.00
PERK activation preserves the viability and function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases. Am J Pathol (2013) 1.00
Regulation of experimental autoimmune encephalomyelitis by TPL-2 kinase. J Immunol (2014) 0.96
Evaluation of a transgenic mouse model of multiple sclerosis with noninvasive methods. Invest Ophthalmol Vis Sci (2011) 0.95
A single dose of neuron-binding human monoclonal antibody improves spontaneous activity in a murine model of demyelination. PLoS One (2011) 0.94
Active immunization using a single dose immunotherapeutic abates established EAE via IL-10 and regulatory T cells. Eur J Immunol (2010) 0.91
Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines. Vaccine (2010) 0.91
Oxidative and nitrative stress in neurodegeneration. Neurobiol Dis (2015) 0.90
Understanding disease processes in multiple sclerosis through magnetic resonance imaging studies in animal models. Neuroimage Clin (2014) 0.88
Transfer of myelin-reactive th17 cells impairs endogenous remyelination in the central nervous system of cuprizone-fed mice. J Neurosci (2015) 0.86
Inhibitors of myelination: ECM changes, CSPGs and PTPs. Exp Neurol (2013) 0.86
CD8(+) T cells in multiple sclerosis. Expert Opin Ther Targets (2013) 0.86
Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis. Neuropharmacology (2015) 0.83
Contrasting roles for CD4 vs. CD8 T-cells in a murine model of virally induced "T1 black hole" formation. PLoS One (2012) 0.82
The unfolded protein response in multiple sclerosis. Front Neurosci (2015) 0.82
Progesterone alleviates neural behavioral deficits and demyelination with reduced degeneration of oligodendroglial cells in cuprizone-induced mice. PLoS One (2013) 0.82
Multiple sclerosis: experimental models and reality. Acta Neuropathol (2016) 0.82
Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis). J Neuroimmunol (2014) 0.81
Theiler's murine encephalomyelitis virus as an experimental model system to study the mechanism of blood-brain barrier disruption. J Neurovirol (2013) 0.81
Promotion of remyelination by adipose mesenchymal stem cell transplantation in a cuprizone model of multiple sclerosis. Cell J (2013) 0.81
Precision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive Astrocytes. Front Mol Neurosci (2016) 0.80
CMV infection attenuates the disease course in a murine model of multiple sclerosis. PLoS One (2012) 0.79
Correlation of Brain Atrophy, Disability, and Spinal Cord Atrophy in a Murine Model of Multiple Sclerosis. J Neuroimaging (2015) 0.79
Progressive multiple sclerosis. Curr Opin Neurol (2015) 0.78
Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders. Bioanalysis (2012) 0.78
Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy. Neurotherapeutics (2013) 0.78
Mesenchymal properties of SJL mice-stem cells and their efficacy as autologous therapy in a relapsing-remitting multiple sclerosis model. Stem Cell Res Ther (2014) 0.78
Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis. Neurol Res Int (2011) 0.78
Anti-myelin antibodies play an important role in the susceptibility to develop proteolipid protein-induced experimental autoimmune encephalomyelitis. Clin Exp Immunol (2014) 0.78
Spontaneous ocular and neurologic deficits in transgenic mouse models of multiple sclerosis and noninvasive investigative modalities: a review. Invest Ophthalmol Vis Sci (2012) 0.77
Inherited and acquired disorders of myelin: The underlying myelin pathology. Exp Neurol (2016) 0.77
Tolerogenic vaccines for Multiple sclerosis. Hum Vaccin Immunother (2013) 0.77
Emotional change-associated T cell mobilization at the early stage of a mouse model of multiple sclerosis. Front Immunol (2013) 0.77
Targeting epidermal fatty acid binding protein for treatment of experimental autoimmune encephalomyelitis. BMC Immunol (2015) 0.76
Deletion of Virus-specific T-cells Enhances Remyelination in a Model of Multiple Sclerosis. J Neurol Transl Neurosci (2014) 0.76
Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases. Crit Rev Immunol (2015) 0.75
Cuprizone demyelination induces a unique inflammatory response in the subventricular zone. J Neuroinflammation (2016) 0.75
Unresolved issues in theories of autoimmune disease using myocarditis as a framework. J Theor Biol (2014) 0.75
Inhibition of Drp1 hyper-activation is protective in animal models of experimental multiple sclerosis. Exp Neurol (2017) 0.75
Development and Pre-Clinical Evaluation of Recombinant Human Myelin Basic Protein Nano Therapeutic Vaccine in Experimental Autoimmune Encephalomyelitis Mice Animal Model. Sci Rep (2017) 0.75
NF-κB activation protects oligodendrocytes against inflammation. J Neurosci (2017) 0.75
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
Multiple sclerosis. N Engl J Med (2000) 12.69
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol (2000) 9.73
SPONTANEOUS ENCEPHALOMYELITIS OF MICE--A NEW VIRUS DISEASE. Science (1934) 9.02
Induction and effector functions of T(H)17 cells. Nature (2008) 7.75
Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect Immun (1975) 7.12
ENCEPHALOMYELITIS ACCOMPANIED BY MYELIN DESTRUCTION EXPERIMENTALLY PRODUCED IN MONKEYS. J Exp Med (1935) 5.01
Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol (2007) 5.01
Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med (2000) 3.84
The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol (2001) 3.47
Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med (1997) 3.46
Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol (2005) 3.34
Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol (1981) 3.15
Clinical viral infections and multiple sclerosis. Lancet (1985) 3.12
Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA (2001) 3.07
OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS. J Exp Med (1933) 3.03
Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol (2000) 2.99
Rapid Production of Acute Disseminated Encephalomyelitis in Rhesus Monkeys by Injection of Brain Tissue With Adjuvants. Science (1946) 2.88
A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med (2001) 2.81
Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. Ann Neurol (1983) 2.60
Theiler's virus-induced demyelination: prevention by immunosuppression. Science (1976) 2.59
Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology (2008) 2.41
How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol (2006) 2.38
Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol (2001) 2.27
The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol (2007) 2.19
Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol (1986) 2.06
The predominant virus antigen burden is present in macrophages in Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Virol (1995) 2.06
Demyelination induced by Theiler's virus: influence of the H-2 haplotype. J Immunol (1985) 1.98
Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci (2002) 1.80
Multiple sclerosis. Animal model:Theiler's virus infection in mice. Am J Pathol (1977) 1.73
Multiple sclerosis (first of two parts). N Engl J Med (1982) 1.72
Theiler's murine encephalomyelitis: a model of demyelination and persistence of virus. Crit Rev Immunol (1987) 1.65
Remyelination in experimental models of toxin-induced demyelination. Curr Top Microbiol Immunol (2008) 1.57
Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat Med (1998) 1.49
The effect of injections of lysophosphatidyl choline into white matter of the adult mouse spinal cord. J Cell Sci (1972) 1.45
Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination. Glia (1999) 1.37
A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest (2001) 1.31
Epidemiologic contributions to multiple sclerosis: an overview. Neurology (1980) 1.28
Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis (2006) 1.26
Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination. Springer Semin Immunopathol (2002) 1.24
Status spongiosus of CNS and hepatic changes induced by cuprizone (biscyclohexanone oxalyldihydrazone). Am J Pathol (1969) 1.24
Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J Clin Invest (1999) 1.23
The TO strains of Theiler's viruses cause "slow virus-like" infections in mice. Ann Neurol (1979) 1.23
The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol (2004) 1.23
The pathology of multiple sclerosis. Neurol Clin (2005) 1.22
Remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. J Neurocytol (1995) 1.20
Multiple sclerosis (second of two parts). N Engl J Med (1982) 1.18
Theiler's Murine Encephalomyelitis Virus (TMEV)-Induced Demyelination: A Model for Human Multiple Sclerosis Methods (1996) 1.15
Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease. Curr Allergy Asthma Rep (2003) 1.14
Efficient central nervous system remyelination requires T cells. Ann Neurol (2003) 1.11
A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J (2004) 1.08
Acute hemorrhagic demyelination in a murine model of multiple sclerosis. J Neuroinflammation (2008) 1.07
Multiple sclerosis: pathogenesis and MR imaging features of T1 hypointensities in a [corrected] murine model. Radiology (2008) 0.98
Functional activation of myelin-specific T cells by virus-induced molecular mimicry. J Immunol (2002) 0.96
Genetically dominant spinal cord repair in a murine model of chronic progressive multiple sclerosis. J Neuropathol Exp Neurol (2005) 0.94
Direct comparison of demyelinating disease induced by the Daniel's strain and BeAn strain of Theiler's murine encephalomyelitis virus. Brain Pathol (2003) 0.92
Deep gray matter T2 hypointensity correlates with disability in a murine model of MS. J Neurol Sci (2009) 0.91
Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J (2002) 0.88
Dynamics of MRI lesion development in an animal model of viral-induced acute progressive CNS demyelination. Neuroimage (2004) 0.87
Contrasting murine models of MS. Int MS J (2004) 0.83
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease. J Neuropathol Exp Neurol (1947) 0.81
Pathogenesis of multiple sclerosis. A critical reappraisal. Acta Neuropathol (1986) 0.80
Cuprizone neurotoxicity in the rat: morphologic observations. J Neurol Sci (1988) 0.79
Spongiform encephalopathy induced in rats and guinea pigs by cuprizone. Exp Mol Pathol (1969) 0.78
Role of viruses in the etiopathogenesis of multiple sclerosis. Acta Neurol (Napoli) (1993) 0.77
Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol (2004) 2.84
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study. Arch Neurol (2004) 2.37
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Hip arthroplasty. Lancet (2012) 1.73
Retracted Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med (2002) 1.68
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology (2013) 1.48
Revision total hip arthroplasty in Jehovah's Witnesses. Orthopedics (2012) 1.40
Induction of blood brain barrier tight junction protein alterations by CD8 T cells. PLoS One (2008) 1.38
Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol (2004) 1.36
Survival of hard-on-hard bearings in total hip arthroplasty: a systematic review. Clin Orthop Relat Res (2011) 1.28
Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis (2006) 1.26
Retracted Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity. Cancer Res (2004) 1.26
Clearance of Theiler's virus infection depends on the ability to generate a CD8+ T cell response against a single immunodominant viral peptide. Eur J Immunol (2003) 1.25
Retracted Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. J Immunol (2003) 1.21
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain (2010) 1.19
CD8 T cell-initiated vascular endothelial growth factor expression promotes central nervous system vascular permeability under neuroinflammatory conditions. J Immunol (2009) 1.17
Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnol J (2009) 1.15
A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res (2007) 1.15
Interleukin-6 protects anterior horn neurons from lethal virus-induced injury. J Neurosci (2003) 1.15
Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs (2009) 1.14
Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci (2003) 1.14
CD8+ T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in a viral model of fulminant demyelination. J Neuroimmunol (2007) 1.12
Efficient central nervous system remyelination requires T cells. Ann Neurol (2003) 1.11
The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis. Neurol Res (2006) 1.11
Antigen-specific CD8+ T cells mediate a peptide-induced fatal syndrome. J Immunol (2005) 1.09
Retracted Blockade of allergic airway inflammation following systemic treatment with a B7-dendritic cell (PD-L2) cross-linking human antibody. J Immunol (2004) 1.09
A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J (2004) 1.08
Reduced dislocation rates and excellent functional outcomes with large-diameter femoral heads. J Arthroplasty (2013) 1.08
Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol (2004) 1.08
Advance pre-operative chlorhexidine reduces the incidence of surgical site infections in knee arthroplasty. Int Orthop (2010) 1.08
Acute hemorrhagic demyelination in a murine model of multiple sclerosis. J Neuroinflammation (2008) 1.07
Demyelinated axons and motor function are protected by genetic deletion of perforin in a mouse model of multiple sclerosis. J Neuropathol Exp Neurol (2009) 1.06
Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia (2002) 1.06
Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem (2008) 1.06
Prophylactic oral antibiotics reduce reinfection rates following two-stage revision total knee arthroplasty. Int Orthop (2010) 1.05
HLA DR and DQ interaction in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in HLA class II transgenic mice. J Neuroimmunol (2005) 1.04
Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol (2012) 1.04
Identification of T cell epitopes on human proteolipid protein and induction of experimental autoimmune encephalomyelitis in HLA class II-transgenic mice. Eur J Immunol (2004) 1.04
Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J (2002) 1.04
Disrupted spatial memory is a consequence of picornavirus infection. Neurobiol Dis (2006) 1.04
Enzymatic properties of rat myelencephalon-specific protease. Biochemistry (2002) 1.03
The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology? Int Rev Neurobiol (2007) 1.02
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler (2012) 1.01
Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch Neurol (2006) 1.01
Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J (2004) 1.01
Intracerebral hemorrhage leads to infiltration of several leukocyte populations with concomitant pathophysiological changes. J Cereb Blood Flow Metab (2008) 0.99
CD8+ T cells cause disability and axon loss in a mouse model of multiple sclerosis. PLoS One (2010) 0.99
Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Mov Disord (2004) 0.99
Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis (2004) 0.99
Increased revision rates after total knee arthroplasty in patients who smoke. J Arthroplasty (2012) 0.99
Multiple sclerosis: pathogenesis and MR imaging features of T1 hypointensities in a [corrected] murine model. Radiology (2008) 0.98
Brainstem 1H nuclear magnetic resonance (NMR) spectroscopy: marker of demyelination and repair in spinal cord. Ann Neurol (2009) 0.98
Magnetic resonance imaging, microscopy, and spectroscopy of the central nervous system in experimental animals. NeuroRx (2005) 0.97
Efficacy of erythrocyte sedimentation rate and C-reactive protein level in determining periprosthetic hip infections. Am J Orthop (Belle Mead NJ) (2012) 0.97
Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) (2013) 0.96
HLA-DQ6 (DQB1*0601)-restricted T cells protect against experimental autoimmune encephalomyelitis in HLA-DR3.DQ6 double-transgenic mice by generating anti-inflammatory IFN-gamma. J Immunol (2008) 0.95
Facile assembly of micro- and nanoarrays for sensing with natural cell membranes. ACS Nano (2011) 0.95
Genetically dominant spinal cord repair in a murine model of chronic progressive multiple sclerosis. J Neuropathol Exp Neurol (2005) 0.94
MRI in rodent models of brain disorders. Neurotherapeutics (2011) 0.94
A single dose of neuron-binding human monoclonal antibody improves spontaneous activity in a murine model of demyelination. PLoS One (2011) 0.94
CD8 T cell-initiated blood-brain barrier disruption is independent of neutrophil support. J Immunol (2012) 0.94
A hematopoietic contribution to microhemorrhage formation during antiviral CD8 T cell-initiated blood-brain barrier disruption. J Neuroinflammation (2012) 0.94
Is multiple sclerosis an autoimmune disease? Autoimmune Dis (2012) 0.94
Dual-mobility bearings: a review of the literature. Expert Rev Med Devices (2012) 0.93
Pediatric multiple sclerosis. Neurol Clin (2011) 0.93
Modulation of peripheral cytotoxic cells and ictogenesis in a model of seizures. Epilepsia (2011) 0.93
Invited article: human natural autoantibodies in the treatment of neurologic disease. Neurology (2009) 0.93
Direct comparison of demyelinating disease induced by the Daniel's strain and BeAn strain of Theiler's murine encephalomyelitis virus. Brain Pathol (2003) 0.92